AngioDynamics, Inc. (NASDAQ:ANGO) Stock Holdings Increased by Connor Clark & Lunn Investment Management Ltd.

Posted by Defense World Staff on Aug 25th, 2023

Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) by 25.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,147 shares of the medical instruments supplier’s stock after acquiring an additional 12,903 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.16% of AngioDynamics worth $663,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd bought a new stake in AngioDynamics during the 1st quarter valued at $36,000. CWM LLC raised its stake in shares of AngioDynamics by 1,048.0% in the 4th quarter. CWM LLC now owns 2,032 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 1,855 shares in the last quarter. Captrust Financial Advisors raised its stake in shares of AngioDynamics by 95.1% in the 1st quarter. Captrust Financial Advisors now owns 2,883 shares of the medical instruments supplier’s stock worth $62,000 after buying an additional 1,405 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of AngioDynamics by 187.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 4,442 shares of the medical instruments supplier’s stock worth $91,000 after buying an additional 2,895 shares in the last quarter. Finally, UBS Group AG raised its stake in shares of AngioDynamics by 764.3% in the 3rd quarter. UBS Group AG now owns 5,670 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 5,014 shares in the last quarter. Institutional investors own 92.82% of the company’s stock.

AngioDynamics Stock Down 3.8 %

Shares of AngioDynamics stock opened at $8.43 on Friday. The stock’s fifty day moving average is $9.35 and its 200-day moving average is $10.20. The firm has a market capitalization of $334.42 million, a PE ratio of -6.39 and a beta of 0.61. The company has a quick ratio of 1.29, a current ratio of 1.95 and a debt-to-equity ratio of 0.13. AngioDynamics, Inc. has a 12-month low of $8.06 and a 12-month high of $23.32.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last issued its quarterly earnings results on Wednesday, July 12th. The medical instruments supplier reported $0.02 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.02. AngioDynamics had a negative return on equity of 0.61% and a negative net margin of 15.48%. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $90.73 million. During the same quarter in the previous year, the company posted $0.01 earnings per share. AngioDynamics’s revenue for the quarter was up 4.7% compared to the same quarter last year. Equities analysts anticipate that AngioDynamics, Inc. will post -0.32 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. StockNews.com assumed coverage on AngioDynamics in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. Canaccord Genuity Group boosted their price objective on AngioDynamics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, July 13th.

View Our Latest Report on ANGO

AngioDynamics Company Profile

(Free Report)

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.